FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 963 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 Opinion: ‘Why we need earlier diagnosis of cancer more than ever... February 3, 2021 Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma August 10, 2023 Load more HOT NEWS Breast Cancer Warrior’s Emotional Photoshoot Features Her Husband Shaving Her Head Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly...
